NFKB1 and breast carcinoma: Specifically, clofibrate inhibits the growth of breast cancer cells by inhibiting the activation of NF-κB and extracellular regulatory protein kinase 1/2 (ERK1/2), inhibiting the cyclin factor cyclin D1, cyclin A, and cyclin E, leading to cell cycle arrest and inducing pro-apoptotic factor P21 levels (Rakhshandehroo et al., 2010; Chandran et al., 2016).